Better understanding of wound healing could lead to improved treatment(s) of multiple sclerosis (MS) and psoriasis (Pso).
Recent Advances:
New concepts in the events of wound healing, such as the roles of the innate and adaptive immune systems, have generated targets for treating these debilitating diseases.
Innovation:
That in MS and Pso defective wound healing is responsible for the diseases' progression has not been hypothesized to date.
Conclusion:
Impaired initiation of wound repair by oligodendrocyte precursor cells or oligodendrocytes may play a role in MS, and a lack of inhibition of the proliferative phase in wound healing may explain the pathophysiology involved in Pso.
Get full access to this article
View all access options for this article.
References
1.
RaychaudhuriSP, JiangW-Y, RaychaudhuriSK. Revisiting the Koebner phenomenon. Am J Pathol, 2008; 172:961–971.
2.
LarnerAJ. Who named it?. J Neurol Neurosurg Psych, 2003; 74:1614.
3.
MorhennVB, NelsonTE, GruolDL. The rate of wound healing is increased in psoriasis. J Dermatol Sci, 2013; 72:87–92.
4.
SchauberJ, DorschnerRA, CodaAB, et al.Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D–dependent mechanism. J Clin Invest, 2007; 117:803–811.
5.
FrankS, StallmeyerB, KaempferH, KolbN, PfeilschifterJ. Nitric oxide triggers enhanced induction of vascular endothelial growth factor expression in cultured keratinocytes (HaCaT) and during cutaneous wound repair. FASEB J, 1999; 13:2002–2014.
6.
ChangHR, TsaoDA, WangSR, YuHS. Expression of nitric oxide synthases in keratinocytes after UVB irradiation. Arch Dermatol Res, 2003; 295:293–296.
7.
Szterling-JaworowskaM, Szterling-JaworowskaM, BaranA, MyśliwiecH, FlisiakI. Effect of psoriasis activity and topical treatment on plasma epidermal growth factor (EGF) and its soluble receptor (sEGFR). J Dermatolog Treat, 2017; 16:1–5.
8.
JiangM, LiB, ZhangJ, HuL, DangE, WangG. Vascular endothelial growth factor driving aberrant keratin expression pattern contributes to the pathogenesis of psoriasis. Exp Cell Res, 2017; 360:310–316.
9.
NickoloffBJ, BonishBK, MarbleDJ, et al.Lessons from psoriatic plaques concerning mechanisms of tissue repair, remodeling, and inflammation. J Investig Dermatol Symp Proc, 2006; 11:16–29.
10.
BhushanM, McLaughlinB, WeissJB, GriffithsCE. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol, 1999; 141:1054–1060.
11.
WilgusTA, MatthiesAM, RadekKA, et al.Novel function for vascular endothelial growth factor receptor-1 on epidermal keratinocytes. Am J Pathol, 2005; 67:1257–1266.
12.
DetmarM, BrownLF, ClaffeyKP, et al.Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med, 1994; 180:1141–1146.
13.
MorhennVB, WalehNS, MansbridgeJN, et al.Evidence for an NMDA receptor subunit in human keratinocytes and rat cardiocytes. Eur J Pharmacol, 1994; 268:409–414.
14.
BurzomatoV, FrugierG, Pérez-OtañoI, KittlerJT, AtwellD. The receptor subunits generating NMDA receptor mediated currents in oligodendrocytes. J Physiol, 2010; 15:3403–3414.
15.
MorhennVB, MurakamiM, O'GradyT, NordbergJ, GalloRL. Characterization of expression of the NMDA receptor in keratinocytes. Exp Dermatol, 2004; 13:505–511.
16.
LiC, XiaoL, LiuX, et al.A functional role of the NMDA-receptor is regulating the differentiation of oligodendrocyte precursor cells and remyelination of nerves. Glia, 2013; 61:732–749.
17.
SlonieckaM, Le RouxS, BomanP, ByströmB, ZhouQ, DanielsonP. Expression profiles of neuropeptides, neurotransmitters, and their receptors in human keratocytes in vitro and in situ. PLoS One, 2015; 10:e0134157.
18.
GrandoS. Muscarinic receptor agonists and antagonists: effects on keratinocyte functions. Handb Exp Pharmacol, 2012; 208:429–445.
19.
KishibeM, GriffinTM, RadekKA. Keratinocyte nicotinic acetylcholine receptor activation modulates early TLR2-mediated wound healing responses. Int Immunopharmacol, 2015; 29:63–70.
DeshmukhVA, TardifV, LysiotisCA, et al.A regenerative approach to the treatment of multiple sclerosis. Nature, 2013; 502:327–332.
22.
CrunkhornS. Autoimmune disease: Parkinsons' drug promotes myelin repair. Nat Rev Drug Discov, 2013; 12:905.
23.
RosettoO.The binding of botulinum neurotoxins to different peripheral neurons. Toxicon, 2018; 147:27–31.
24.
GilbertE, WardNL. Efficacy of botulinum neurotoxin type A for treating recalcitrant plaque psoriasis. J Drugs Dermatol, 2014; 13:1407–1408.
25.
AndreadouE, KemanetzoglounE, BrokalakiCh, et al.Demyelinating disease following anti-TNFa treatment: a causal or coincidental association? Report of four cases and review of the literature. Case Rep Neurol Med, 2013; 2013:671935.
26.
EgebergA, MallbrisL, GislasonGH, SkovL, HansenPR. Risk of multiple sclerosis in patients with psoriasis: a Danish Cohort Study. J Invest Dermatol, 2016; 136:93–98.
27.
CollamerAN, BattafaranoDF. Psoriatic skin lesions induced by tumor necrosis antagonist therapy: clinical features and possible immonopathogenesis. Semin Arthritis Rheum, 2010; 40:233–240.
28.
Djelilovic-VranicJ, AlajbegovicA, Tiric-CamparaM, et al.Stress as provoking factor for the first and repeated multiple sclerosis seizures. Mater Sociomed, 2012; 24:142–147.
29.
MorhennVB. Treating multiple sclerosis with an anticholinergic drug causes changes in the skin. J Mult Scler, 2017; 4:1–2.
30.
MacLeodAS, MansbridgeJN. The innate immune system in acute and chronic wounds. Adv Wound Care, 2016; 5:65–78.
31.
MorizaneS, GalloRJ. Antimicrobial peptides in the pathogenesis of psoriasis. J Dermatol, 2012; 39:225–230.
